SPPAM
CSTL icon

Summit Partners Public Asset Management’s Castle Biosciences CSTL Stock Holding History

Summit Partners Public Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.1M Sell
940,685
-118,040
-11% -$3.87M 0.62% 55
2025
Q4 		$41.2M Buy
1,058,725
+658,725
+165% +$21.2M 0.86% 42
2025
Q3 		$9.11M Buy
+400,000
New +$8.13M 0.19% 108

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Partners Public Asset Management's CSTL Position: Q1 2026 in Review

Summit Partners Public Asset Management reduced its Castle Biosciences (CSTL) stake by 11% in Q1 2026, selling an estimated $3.87M and leaving 940,685 shares worth $23.1M. The position accounts for 0.62% of the portfolio, ranked #55.

Summit Partners Public Asset Management first reported a position in CSTL in Q3 2025 and has held it in 3 quarters since. The position peaked at $41.2M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Summit Partners Public Asset Management held 940,685 shares of Castle Biosciences worth $23.1M as of Q1 2026.
  • Summit Partners Public Asset Management sold 118,040 Castle Biosciences shares in Q1 2026, an estimated $3.87M.
  • Castle Biosciences made up 0.62% of Summit Partners Public Asset Management's portfolio in Q1 2026, its #55 holding.
  • Summit Partners Public Asset Management first reported a position in Castle Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Summit Partners Public Asset Management's Castle Biosciences position peaked at $41.2M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2026, filed 15 May 2026.